CHAIR
:
SPEAKER
(S):
Ling Su,
PhD (SPKNON), Strategic Advisor, Life Sciences,
Sidley Austin LLP, China
Ling Su has nearly 20 years of experience in in the pharmaceutical industry and the regulatory agency, in both US and Asia. His interests include clinical research, regulatory affairs, drug safety and pharmacoepidemiology.
|
Mey Wang, PhD (SPKAGY), Reviewer, Division of New Drugs, Center for Drug Evaluation, Taiwan
Zhen Chen, PhD (SPKAGY), Deputy Office Director, Office of New Drug Pharmaceutical Science, Center for Drug Evaluation of CFDA, China
Hsin-Jung Lee, (SPKAGY), Reviewer, Division of New Drugs, Center for Drug Evaluation, Taiwan
Yi Feng,
(SPKAGY), Office of Evaluation Management and Communication,
Center for Drug Evaluation of CFDA, China
Mr. Yi Feng is the director of Office of Review Management, Center for Drug Evaluation (CDE), SFDA. Prior to CDE, SFDA, he worked at Academy of Military Medical Sciences.
|
Description
In this forum, representatives from the Center of Drug Evaluation from mainland China and the Center for Drug Evaluation from Taiwan will share their views and experience in Good Review Practice (GRP) and IND review. This will form the basis for the discussion of collaboration opportunities and areas of convergence in regulatory science in the two centers.